Abstract:BACKGROUND: Hepatocellular carcinoma (HCC) is a common type of cancer that shows great morbidity and mortality rates. However, there are limited available drugs to treat HCC.AIM: The present work focused on discovering the potential anti-HCC compounds from traditional Chinese medicine (TCM) by employing high-throughput sequencing-based high-throughput screening (HTS<sup>2</sup>) together with the liver cancer pathway-associated gene signature.METHODS: HTS<sup>2</sup> assay was adopted for identifying herbs. Protein-protein interaction (PPI) network analysis and computer-aided drug design (CADD) were used to identify key targets and screen the candidate natural products of herbs. Molecular docking, network pharmacology analysis, western blotting, immunofluorescent staining, subcellular fractionation experiment, dual-luciferase reporter gene assay, surface plasmon resonance (SPR) as well as nuclear magnetic resonance (NMR) were performed to validate the ability of compound binding with key target and inhibiting its function. Moreover, cell viability, colony-forming, cell cycle assay and animal experiments were performed to examine the inhibitory effect of compound on HCC.RESULTS: We examined the perturbation of 578 herb extracts on the expression of 84 genes from the liver cancer pathway, and identified the top 20 herbs significantly reverting the gene expression of this pathway. Signal transducer and activator of transcription 3 (STAT3) was identified as one of the key targets of the liver cancer pathway by PPI network analysis. Then, by analyzing compounds from top 20 herbs utilizing CADD, we found ginsenoside F2 (GF2) binds to STAT3 with high affinity, which was further validated by the results from molecular docking, SPR and NMR. Additionally, our results showed that GF2 suppresses the phosphorylation of Y705 of STAT3, inhibits its nuclear translocation, decreases its transcriptional activity and inhibits the growth of HCC in vitro and in vivo.CONCLUSION: Based on this large-scale transcriptional study, a number of anti-HCC herbs were identified. GF2, a compound derived from TCM, was found to be a chemical basis of these herbs in treating HCC. The present work also discovered that GF2 is a new STAT3 inhibitor, which is able to suppress HCC. As such, GF2 represents a new potential anti-HCC therapeutic strategy.

Rational discovery of novel type-III FTF antagonists to competitively suppress TIF-2 coactivation in liver cancer

Discovery of 2-Aminopyrimidine Derivatives As Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced Herg Inhibitory Activities.

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors

Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma

Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells

Structure‐Activity Relationships of 2‐(Arylthio)benzoic Acid FTO Inhibitors

Discovery of Novel 7-Azaindole Derivatives As Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma

Identification of novel inhibitors of the transcriptional coactivator MRTF-A for HCC therapy

A large-scale transcriptional analysis reveals herb-derived ginsenoside F2 suppressing hepatocellular carcinoma via inhibiting STAT3

Design, synthesis and biological evaluation of novel FAK inhibitors with better selectivity over IR than TAE226

A Novel Small-Molecule Inhibitor of Trefoil Factor 3 (TFF3) Potentiates MEK1/2 Inhibition in Lung Adenocarcinoma

Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 Via Structure-Based Virtual Screening and Biological Evaluation in in Vitro Models

Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction Against Hepatocellular Carcinoma Via the Modulation of Microrna Biogenesis.

CFI-402257, a TTK inhibitor, effectively suppresses hepatocellular carcinoma

A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects

Discovery of Ureido-Substituted 4-Phenylthiazole Derivatives as IGF1R Inhibitors with Potent Antiproliferative Properties

Discovery of a small molecule ligand of FRS2 that inhibits invasion and tumor growth

Anti-Inflammatory Activity in Vitro and in Vivo of the Protein Farnesyltransferase Inhibitor Tipifarnib

Discovery of 1,6-Naphthyridin-2(1 H )-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma